martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 9, 2026

JPM Q4 Earnings on Deck: Buy, Sell or Hold the Stock Ahead of Results?

View original at finance.yahoo.com
JPM Q4 Earnings on Deck: Buy, Sell or Hold the Stock Ahead of Results? JPMorgan JPM is slated to report fourth-quarter and full-year 2025 earnings on Jan…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • JPMorgan's earnings are closely watched for clues about the broader financial sector and are often seen as a bellwether for how other banks may perform

    80% confidence
  • Existing shareholders may continue to hold JPM stock, given its strong fundamentals and proven resilience. Potential investors should carefully weigh factors and assess risk tolerance before initiating new positions

    80% confidence
  • JPMorgan expects to record a $2.2 billion provision for credit losses in fourth-quarter 2025 tied to its forward purchase commitment for Apple Card

    80% confidence
  • The chances of an earnings beat for JPMorgan are low this time based on Earnings ESP of -0.03% and Zacks Rank #3

    80% confidence
  • Management expects markets revenues in the fourth quarter to rise at a low-teens percentage rate on a year-over-year basis

    80% confidence
  • IB revenues in the fourth quarter are expected to increase in the low single digit

    80% confidence
  • Management expects NII to reach almost $25 billion in the fourth quarter of 2025, which implies a full-year NII of approximately $95.8 billion

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
JPM Q4 Earnings on Deck: Buy, Sell or Hold the Stock Ahead of Results? — Source | Via News | es.VIA.NEWS